# Intrahepatic, perihilar, distal and gallbladder cancer

Source: https://onco.cc/terms/biliary-anatomy-subtypes/  
OnCo record `biliary-anatomy-subtypes` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bile duct cancers are named by where they start: inside the liver, at the hilum where the ducts join, in the lower duct near the pancreas, or in the gallbladder. Each behaves and mutates differently.

## Summary

Intrahepatic cholangiocarcinoma (iCCA) carries FGFR2 fusions (~10-15%) and IDH1 mutations (~15%) and is rising in incidence; perihilar (Klatskin) and distal tumours are more often HER2-amplified or KRAS-mutant; gallbladder cancer has the highest HER2 prevalence (~15-20%) and is common in Chile, India and among Indigenous Americans. Molecular profiling is guideline-recommended for all advanced biliary cancers.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cholangiocarcinoma
- Wikipedia: https://en.wikipedia.org/wiki/Cholangiocarcinoma

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Cystic duct carcinoma](https://onco.cc/cancers/cystic-duct-carcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/), [HER2](https://onco.cc/targets/her2/), [IDH1 / IDH2](https://onco.cc/targets/idh/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/biliary-anatomy-subtypes.json